Trabectedin is named as an intervention in 6 current clinical trials in our France, Italy, Germany, Spain, USA and Canada registers. 6 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Italian Sarcoma Group (2). The most-studied condition is Soft Tissue Sarcoma. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Trabectedin was first approved in the EU on 17 Sep 2007. It is approved in 3 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Trabectedin. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Multicentre, randomized, open label study comparing the concomitant administration of trabectedin and low-dose radiotherapy versus trabectedin alone in patients with advanced sarcoma
2026-525703-27-00 · Musculoskeletal Diseases
|
Phase 4 | Authorised | Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz | Spain |
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
6 single-substance products containing Trabectedin on the HPRA medicines list.
No entry for Trabectedin in the EMA, FDA or German BfArM shortage lists we track.
| Lead sponsor | Trials |
|---|---|
| Italian Sarcoma Group | 2 |
| Intensity Therapeutics, Inc | 1 |
| Universität Münster | 1 |
| UNICANCER | 1 |
| Grupo Espanol de Investigacion en Sarcomas | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in France | 3 | 3 |
| Clinical trials in Italy | 3 | 3 |
| Clinical trials in Germany | 2 | 2 |
| Clinical trials in Spain | 2 | 2 |
| Clinical trials in USA | 1 | 1 |
| Clinical trials in Canada | 1 | 1 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
6 current trials in our France, Italy, Germany, Spain, USA and Canada registers name Trabectedin as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 6 of the 6 trials are recruiting: 3 with sites in France, 3 with sites in Italy, 2 with sites in Germany, 2 with sites in Spain, 1 with sites in USA and 1 with sites in Canada. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Italian Sarcoma Group (2), Intensity Therapeutics, Inc (1), Universität Münster (1) and UNICANCER (1), among 5 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 6 single-substance products containing Trabectedin, for example Trabectedin Accord 0.25 mg powder for concentrate for solution for infusion (Accord Healthcare S.L.U.). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Trabectedin has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Trabectedin works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Trabectedin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Trabectedin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.